EN DE

SciVision Biotech Inc (1786) Fair Value & Analysis

Healthcare · TW · Market cap 3.6B TWD

SB SciVision Biotech Inc 1786 · TW
Price51.80 TWD
Fair Value50.28 TWD
Upside-2.9%
Quality54/100
Watch SciVision Biotech Inc for free, get notified when fair value or trend changes. Watch for free
Expensive Growth
Solidly profitable · 14.4% net margin
Low debt · generates free cash flow
Mixed vs. peers (6/14)
Moderate moat 49/100
Evidence: High Range 26.98 TWD – 61.89 TWD Share as image

Fair value as of: Jul 21, 2026

From 26 valuation models · updated 20 days ago

Fair value updated Jul 21, 2026, revised from 47.73 TWD to 50.28 TWD (+5.3%) since Jul 7, 2026. Share price −7.5% over the past month.

A solid business, currently priced close to our fair value.

What matters now

  • The price sits close to our fair value, market and models broadly agree here, little valuation tension.
  • A fairly wide model range (26.98 TWD to 61.89 TWD) leaves room in how you read the outcome.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

136.50 TWD 37.23 TWD Fair Value 50.28 TWD Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 21, 2026.

How to read this chart

60‑month range 37.23 TWD – 136.50 TWD · fair‑value band 26.98 TWD – 61.89 TWD · the 51.80 TWD price screens above the 50.28 TWD fair value. Dashed = 300-day average. As of Jul 21, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

SciVision Biotech Inc (1786) currently trades at 51.80 TWD, while our model-based Fair Value estimate is 50.28 TWD, implying the stock looks roughly 2.9% fairly valued today. The Quality Score stands at 54/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, SciVision Biotech Inc generated revenue of 888M TWD at a net margin of 14.4%. Revenue grew 0.5% year over year. It earns a return on equity of 7.1%. The balance sheet holds a net cash position of 361M TWD. Fundamentals as of Jul 21, 2026

Our scenario range runs from 26.98 TWD (bear case) to 61.89 TWD (bull case); at 51.80 TWD, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 58% below its 52-week high and 1% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -3%, 1786 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF 10.73 TWD 14.51 TWD 20.14 TWD 80
Residual Income 23.24 TWD 24.95 TWD 27.58 TWD 76
Rev-Margin DCF 24.75 TWD 43.78 TWD 70.00 TWD 74
All 26 models by family
DCF Models
FCF DCF 10.84 TWD 14.39 TWD 21.97 TWD 38
Owner Earnings 33.04 TWD 57.93 TWD 103.10 TWD 31
5Y Revenue Exit 24.75 TWD 44.97 TWD 74.41 TWD 39
5Y EBITDA Exit 33.70 TWD 64.55 TWD 105.95 TWD 41
5Y P/E Exit 32.24 TWD 61.35 TWD 97.01 TWD 38
10Y Revenue Exit 19.19 TWD 36.77 TWD 67.51 TWD 36
10Y EBITDA Exit 26.00 TWD 51.29 TWD 94.87 TWD 37
10Y P/E Exit 25.02 TWD 48.91 TWD 87.11 TWD 35
Earnings-Based
Graham-Dodd 15.54 TWD 87.23 TWD 121.17 TWD 54
Lynch FV 24.43 TWD 34.90 TWD 45.36 TWD 50
PEG = 1.0 24.43 TWD 34.90 TWD 45.36 TWD 46
EPV 28.05 TWD 31.43 TWD 34.34 TWD 59
Dividend Discount
Gordon GGM 28.91 TWD 57.61 TWD 87.24 TWD 70
DDM Multi-Stage 28.91 TWD 49.79 TWD 60.82 TWD 61
Multiples
P/E Multiple 37.71 TWD 50.28 TWD 62.84 TWD 63
P/S Multiple 29.14 TWD 38.85 TWD 48.56 TWD 58
P/B Multiple 29.14 TWD 38.85 TWD 48.56 TWD 55
EV/EBIT 40.74 TWD 52.10 TWD 63.46 TWD 53
EV/EBITDA 46.63 TWD 59.95 TWD 73.28 TWD 54
EV/Revenue 30.98 TWD 41.40 TWD 51.83 TWD 43
Asset-Based
NCAV (Graham) 13.94 TWD 18.68 TWD 27.88 TWD 50
Growth DCF
Growth DCF 10.73 TWD 14.51 TWD 20.14 TWD 80
Rev-Margin DCF 24.75 TWD 43.78 TWD 70.00 TWD 74
Economic Profit
Residual Income 23.24 TWD 24.95 TWD 27.58 TWD 76
ROIC Compounder 28.17 TWD 36.46 TWD 44.23 TWD 72
Growth Earnings
Growth-Adj P/E 37.43 TWD 53.47 TWD 69.51 TWD 68

Widest divergence: Growth Earnings (53.47 TWD) versus Growth DCF (14.51 TWD). Highest evidence: Growth DCF (80).

Notify me when 1786 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 888M TWD
Revenue growth (YoY) +0.5%
Net margin 14.4%
Return on equity 7.1%
Free cash flow 22.5M TWD FY2025
P/E ratio 25.9
More key figures
Operating margin 10.4%
EPS (TTM) 2.18 TWD
EPS growth (YoY) -61.8%
Net cash 361M TWD FY2025

Figures from reported company fundamentals · as of Jul 21, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 54/100

Of which business quality 55 · Market factors (momentum, volatility) 28

Profitability 44
Margins and returns on capital today
Quality Growth 16
Are margins and returns improving?
Cashflow 24
Earnings quality: real cash, not paper profit
Fin. Strength 98
Balance sheet, leverage, solvency risk
Investment 53
Disciplined investing over empire-building
Low Volatility 72
Calm price path (market factor)
Momentum 14
Price trend over the last 3–12 months (market factor)
52W Momentum 2
Distance to the 52-week high (market factor)
Net Issuance 97
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

SciVision Biotech Inc. develops and manufactures medical-grade hyaluronic acid products in Taiwan. The company offers synovial fluid supplements, facial dermal implants, absorbable adhesion barriers, and intravesical instillation products.

Full company description

SciVision Biotech Inc. develops and manufactures medical-grade hyaluronic acid products in Taiwan. The company offers synovial fluid supplements, facial dermal implants, absorbable adhesion barriers, and intravesical instillation products. It also involved in international trade; wholesale of medical equipment and cosmetics; and provides management advisory services. SciVision Biotech Inc. was founded in 1990 and is based in Kaohsiung, Taiwan.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

SciVision Biotech Inc reported revenue of 887M TWD in FY2025 versus 506M TWD in FY2021, a compound +15.1%/yr. Reported net income was 162M TWD in FY2025, compounding +12.4%/yr from FY2021.

Growth Quality 62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Latest Revenue (FY 2025)
887M TWD
Latest YoY
+0.4%
Avg. growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+16.7%
Avg. growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+13.7%
Avg. growth/yr (16Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+28.7%
Revenue +15.1%/yr
FY21 506M TWD
FY22 557M TWD
FY23 713M TWD
FY24 883M TWD
FY25 887M TWD
Net income +12.4%/yr
FY21 102M TWD
FY22 142M TWD
FY23 178M TWD
FY24 242M TWD
FY25 162M TWD

Watch 1786: get an alert when its fair value changes →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

SciVision Biotech Inc · Fair Value
50.28 TWD −3%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "SciVision Biotech Inc Fair Value". https://www.fairvalue-calculator.com/stock/1786

Peer Group

Medical Instruments & Supplies · 203 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 54 · Below median
Fair Value upside −3% · Above median
Return on equity (TTM) 7% · Above median
Return on assets 4% · Above median
Net margin (TTM) 14% · Above median
Operating margin (TTM) 10% · Below median
Revenue growth 1% · Below median
Dividend yield (TTM) 0.0% · Bottom 25%
Debt / equity 0.19× · Higher than median

Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper

P/E (TTM) 23.0× · Cheaper than median
P/B 1.80× · Cheaper than median
P/S (TTM) 4.01× · Pricier than median
P/FCF 4.9× · Pricier than median
EV/EBITDA 13.8× · Pricier than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 29 · sector 0
FUTURE 3 · sector 27
PAST 28 · sector 25
HEALTH 91 · sector 96
DIVIDEND 0 · sector 32

Insider activity: 40/100

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).

Stock Price Fair Value vs Fair Value
Intuitive Surgical, Inc ISRG $402.33 $150.04 -63%
EssilorLuxottica Société anonyme 1EL €172.45 €68.55 -60%
Medline Inc MDLN $41.11 $30.15 -27%
Becton, Dickinson and Company BDX $150.65 $103.53 -31%
Alcon Inc ALC $70.26 $39.78 -43%
ResMed Inc RMD $203.87 $187.89 -8%
West Pharmaceutical Services, Inc WST $353.71 $143.97 -59%
Straumann Holding STMN CHF 106.00 CHF 47.31 -55%
Sartorius Stedim Biotech S.A DIM €188.50 €51.16 -73%
Coloplast A/S COLOB kr 414.00 kr 382.22 -8%

Compare SciVision Biotech Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is SciVision Biotech Inc (1786) overvalued or undervalued?
As of Jul 21, 2026, our model estimates a fair value of 50.28 TWD versus a price of 51.80 TWD, about −3% (fairly valued).
What is the fair value of 1786?
Our model-based fair value for SciVision Biotech Inc is 50.28 TWD (as of Jul 21, 2026), built from audited fundamentals. The current price is 51.80 TWD.
What is the quality score of 1786?
SciVision Biotech Inc has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of SciVision Biotech Inc (1786)?
SciVision Biotech Inc reported trailing-twelve-month revenue of about 888M TWD (latest available figure, as of Jul 21, 2026).
What is the net profit margin of 1786?
The net profit margin of SciVision Biotech Inc is about 14.4%, meaning it keeps roughly 14.4% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track SciVision Biotech Inc and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.